Breaking News, Collaborations & Alliances

AbbVie, Gilgamesh Pharma Partner on Next-Gen Psychiatric Therapies

Will leverage AbbVie's psychiatry expertise and Gilgamesh's research platform to develop neuroplastogens to treat psychiatric disorders.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie and Gilgamesh Pharmaceuticals entered a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This collaboration will leverage AbbVie’s expertise in psychiatry and Gilgamesh’s research platform to discover novel neuroplastogens.   Under the agreement, the companies have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders. Upon exercise of the option, AbbVie will lead deve...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters